N-desmethylderamciclane: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 57188424 |
| SCHEMBL ID | 5925679 |
| MeSH ID | M0360858 |
| Synonym |
|---|
| SCHEMBL5925679 |
| 174411-40-6 |
| n-methyl-2-(((1r,2s,4r)-1,7,7-trimethyl-2-phenylbicyclo(2.2.1)hept-2-yl)oxy)ethanamine |
| ee9qme7187 , |
| egis 7056 |
| unii-ee9qme7187 |
| deramciclane metabolite m4 |
| ethanamine, n-methyl-2-(((1r,2s,4r)-1,7,7-trimethyl-2-phenylbicyclo(2.2.1)hept-2-yl)oxy)- |
| n-desmethylderamciclane |
Oral bioavailability of deramciclane and the pharmacokinetic parameters of N-desmethylderamCiclane, the principal metabolite, were determined. The elimination phase half-life of the parent compound is similar after intravenous and oral administration.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The pharmacokinetic properties of deramciclane fumarate (EGIS-3886), a new potential anxiolitic agent, and its N-desmethyl metabolite have been investigated in Wistar rats after 10 mgkg(-1) deramciclane fumarate was administered orally, intraperitoneally or intravenously." | ( Oral, intraperitoneal and intravenous pharmacokinetics of deramciclane and its N-desmethyl metabolite in the rat. Abermann, M; Al-Behaisi, S; Bojti, E; Grézal, G; Klebovich, I; Nemes, KB, 2000) | 0.31 |
| " The aim of this study was to determine the pharmacokinetic parameters of deramciclane after intravenous and oral administration, and its oral bioavailability." | ( Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration. Anttila, M; Björklund, H; Huupponen, R; Paija, O; Rouru, J; Salonen, M, 2003) | 0.32 |
| " Oral bioavailability of deramciclane and the pharmacokinetic parameters of deramciclane and N-desmethylderamciclane, the principal metabolite, were determined after intravenous and oral administration of the parent drug." | ( Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration. Anttila, M; Björklund, H; Huupponen, R; Paija, O; Rouru, J; Salonen, M, 2003) | 0.54 |
| "50h, respectively, and the half-life of the elimination phase was 26." | ( Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration. Anttila, M; Björklund, H; Huupponen, R; Paija, O; Rouru, J; Salonen, M, 2003) | 0.32 |
| " The elimination phase half-life of the parent compound is similar after intravenous and oral administration, whereas the apparent half-life of N-desmethylderamciclane is longer after intravenous than after oral administration of the parent compound." | ( Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration. Anttila, M; Björklund, H; Huupponen, R; Paija, O; Rouru, J; Salonen, M, 2003) | 0.52 |
| " The mean apparent elimination half-life of deramciclane was 24." | ( Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers. Anttila, M; Huupponen, R; Kanerva, H; Miettinen, T; Rouru, J; Scheinin, M, 2004) | 0.6 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Oral bioavailability of deramciclane and the pharmacokinetic parameters of deramciclane and N-desmethylderamciclane, the principal metabolite, were determined after intravenous and oral administration of the parent drug." | ( Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration. Anttila, M; Björklund, H; Huupponen, R; Paija, O; Rouru, J; Salonen, M, 2003) | 0.54 |
| " The mean oral bioavailability of deramciclane was 44% (range 27-58%) and 36% (23-50%) after administration of the oral solution and tablet, respectively." | ( Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration. Anttila, M; Björklund, H; Huupponen, R; Paija, O; Rouru, J; Salonen, M, 2003) | 0.32 |
| " The oral bioavailability of deramciclane is large and uniform enough to allow its clinical use as tablets." | ( Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration. Anttila, M; Björklund, H; Huupponen, R; Paija, O; Rouru, J; Salonen, M, 2003) | 0.32 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "9h after intravenous and about 25 h after oral dosing of the parent compound." | ( Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration. Anttila, M; Björklund, H; Huupponen, R; Paija, O; Rouru, J; Salonen, M, 2003) | 0.32 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (40.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||